Dose Conversion: Concerta 36 mg to Immediate-Release Ritalin
Concerta 36 mg once daily is equivalent to immediate-release methylphenidate (Ritalin) 10 mg three times daily (total 30 mg/day). 1
Conversion Rationale
The FDA-approved Concerta prescribing information provides explicit conversion guidance. When converting from immediate-release methylphenidate to Concerta, 10 mg methylphenidate twice or three times daily converts to Concerta 36 mg every morning. 1 This conversion accounts for the fact that Concerta delivers approximately 20% more total methylphenidate daily than the equivalent immediate-release regimen due to its ascending delivery profile designed to maintain therapeutic coverage throughout 12 hours 2.
Key Pharmacokinetic Differences
When making this conversion, understand that these formulations behave very differently:
- Concerta 36 mg produces a gradually ascending plasma level with an initial plateau at ~3.3 hours and a second plateau at ~6 hours, maintaining coverage for 12 hours 3
- Immediate-release Ritalin 10 mg TID produces three distinct peaks at approximately 30 minutes after each dose, with effects lasting 3-4 hours per dose 2
The total daily methylphenidate exposure is similar between Concerta 36 mg (which contains 36 mg total) and 30 mg of immediate-release methylphenidate given in divided doses, but the delivery pattern differs substantially 4, 3.
Clinical Monitoring After Conversion
After converting from Concerta to immediate-release methylphenidate:
- Expect potential gaps in coverage if only dosing twice daily instead of three times daily
- Monitor for afternoon symptom breakthrough since immediate-release formulations have shorter duration of action 2
- Assess for increased side effects with immediate-release formulations due to higher peak plasma concentrations 3
- Consider timing: Immediate-release doses should be given approximately 4 hours apart to maintain coverage 2
Important Caveats
The reverse conversion (Concerta to immediate-release) may require dose adjustment based on individual response. Some patients may need the full 30 mg/day divided TID, while others may achieve adequate control with lower total daily doses due to the different pharmacokinetic profiles 1. Clinical judgment remains essential, particularly if the patient experiences different efficacy or tolerability with the immediate-release formulation 1.